Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Merck
Moodys
Colorcon

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METHYLPHENIDATE HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Methylphenidate Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Completed New York State Psychiatric Institute N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Completed National Institute on Drug Abuse (NIDA) N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00003266 Methylphenidate in Treating Patients With Melanoma Completed National Cancer Institute (NCI) Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00003266 Methylphenidate in Treating Patients With Melanoma Completed Eastern Cooperative Oncology Group Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Methylphenidate Hydrochloride

Condition Name

Condition Name for Methylphenidate Hydrochloride
Intervention Trials
Attention Deficit Hyperactivity Disorder 93
Attention Deficit Disorder With Hyperactivity 43
ADHD 38
Healthy 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Methylphenidate Hydrochloride
Intervention Trials
Attention Deficit Disorder with Hyperactivity 202
Hyperkinesis 142
Disease 83
Fatigue 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Methylphenidate Hydrochloride

Trials by Country

Trials by Country for Methylphenidate Hydrochloride
Location Trials
United States 598
Canada 31
Israel 24
Germany 21
France 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Methylphenidate Hydrochloride
Location Trials
California 45
Massachusetts 40
New York 38
Texas 38
Ohio 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Methylphenidate Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Methylphenidate Hydrochloride
Clinical Trial Phase Trials
Phase 4 122
Phase 3 81
Phase 2/Phase 3 12
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Methylphenidate Hydrochloride
Clinical Trial Phase Trials
Completed 208
Recruiting 57
Unknown status 33
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Methylphenidate Hydrochloride

Sponsor Name

Sponsor Name for Methylphenidate Hydrochloride
Sponsor Trials
Massachusetts General Hospital 28
National Institute of Mental Health (NIMH) 26
National Institute on Drug Abuse (NIDA) 16
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Methylphenidate Hydrochloride
Sponsor Trials
Other 356
Industry 133
NIH 68
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Moodys
Baxter
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.